Suven Life Sciences announces the randomization of first patient in the Phase-2 clinical trial of Ropanicant (SUVN-911) for the treatment of moderate to severe Major Depressive Disorder (MDD) study in USA.
AI Assistant
Suven Life Sciences Ltd
2024
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.